Kornimate/medical-research-clean huggingface dataset:
glioma: biomolecular aspects

Conditions: Glioma, Malignant

Summary: main limitations in glioma studies are due to the wide heterogeneity and genetic instability of the tumor and to the fact that the molecular informations are static, i.e. obtained on the tumor at its onset. instead, spontaneous or therapy-induced variations are difficult to evaluate and they would need further sampling of the tumor throughout the clinical history. currently these data are more and more routinely used not only for diagnostics but also in the clinical management of the patient. furthermore, microenvironment study is becoming increasingly important. it is also important correlate morpho-functional pathway and brain magnetic resonance. therefore, the main goal of the study is to correlate the data obtained with morphological (site, signal intensity, margins, behavior after contrast medium infusion, mismatch between t2 and flair sequences) and non-morphological mr imaging through a radiomic approach and diffusion and perfusion study, with molecular data relating to the idh mutation, mgmt gene promoter methylation, 1p/19q co-deletion and egfrviii expression. furthermore, it is proposed to carry out a correlation between the radiological data and the mutations found in the ngs panel.


Eligibility criteria:
inclusion criteria: * glioma diagnosis * have performed morphological brain mri or not with contrast medium before surgery * informed consent form exclusion criteria: * patients without magnetic resonance were excluded
an electronic alert system for in-hospital acute kidney injury

Conditions: Acute Kidney Injury

Summary: this study will randomize hospitalized patients with acute kidney injury (aki) to usual care, or an electronic alert intervention. the electronic alert will be in the form of a text page that will be sent to the covering clinician and unit pharmacist once per patient with aki at the time lab results are uploaded. the investigators hypothesize that such an alert will improve outcomes in these patients.


Eligibility criteria:
inclusion criteria: * adults \>=18 years * admitted to the hospital of the university of pennsylvania for greater than 24 hours. exclusion criteria: * dialysis order within 24 hours of admission * dialysis order prior to aki onset * initial creatinine \>=4.0mg/dl * prior admission in which patient was randomized. * nephrectomy during the admission * admission to hospice service * admission to observation status
a real-world registry to investigate the performance of lensx® laser in chinese patients

Conditions: Cataracts

Summary: the purpose of this study is to investigate the performance of lensx® laser in femtosecond laser-assisted cataract surgery (flacs) in real-world medical practice in chinese patients.

all subjects will undergo flacs using the lensx® laser system. the recommended postoperative visits will follow the current standard of care in china.

Eligibility criteria:
inclusion criteria: * chinese; * will undergo lensx® laser-assisted cataract surgery and phacoemulsification in at least one eye; * must sign written informed consent; * other protocol-specified inclusion criteria may apply. exclusion criteria: * contraindications listed in lensx® laser system operator's manual; * pregnant, nursing, or planning a pregnancy; * concurrent enrollment in another investigational drug and/or device study or participation in such a study within 30 days prior to surgery day; * other protocol-specified exclusion criteria may apply.
evaluating the clinical effectiveness of "endotracheal tube position anomaly alerting system"

Conditions: Critical Care Medicine; Mechanical Ventilation; Radiographic Image Interpretation, Computer-Assisted; Alarms

Summary: the goal of this clinical trial is to determine whether the endotracheal tube position anomaly alerting system (etpaas) effectively reduces the duration of endotracheal tube malposition in patients admitted to the intensive care unit (icu). additionally, the study will assess the clinical impact, usability, and user satisfaction of etpaas. the main questions it aims to answer are: * does etpaas reduce the duration of endotracheal tube malposition? * what are healthcare workers' perspectives on the usability and satisfaction of etpaas? participants will receive standard care, with or without etpaas, in the intensive care unit. researchers will evaluate the duration of endotracheal tube malposition. healthcare workers will complete a questionnaire assessing the usability and satisfaction of etpaas.


Eligibility criteria:
inclusion criteria: * patients admitted to the intensive care unit * at least 18 years old exclusion criteria: * patients disagree to participate in the study

Keywords: chest x-ray chest radiograph endotracheal tube intubation, intratracheal
safety and efficacy of ramipril in the treatment of essential hypertension

Conditions: Essential Hypertension

Summary: the purpose of this study is to assess which drug is more effective of ramiprin®(ramipril) and tritace®(ramipril) in the treatment of essential hypertension


Eligibility criteria:
inclusion criteria: * mild and moderate essential hypertension (90mmhg≤dbp≤110mmhg) exclusion criteria: * 180mmhg≤sbp * if differences greater than 20mmhg for sbp and 10mmhg for dbp between both arms are present on 3 consecutive readings * if differences greater than 20mmhg for sbp and 10mmhg for dbp are present on 3 consecutive readings * impaired hepatic function * imapaired renal function * angioedema * aortic valvular stenosis or obstrcutive ejection disorder * primary hyperaldosteronism * renal transplantation, bilateral renal artery stenosis or unilateral stenosis in a single kidney, hemodialysis * severe respiratory disease * congestive heart failure( new york association functional class ⅲ or ⅳ) * malignant hypertension * labile angina pectoris or myocardial infarction in the last 3 months before study entry

Keywords: hypertension ramipril blood pressure artery stiffness bnp crp
osteoporosis in primary hyperparathyroidism

Conditions: Primary Hyperparathyroidism; Osteoporosis

Summary: investigators will prospectively include 40 postmenopausal women with secondary osteoporosis due to primary hyperparathyroidism who have refused surgery. participants will be randomized in two groups and treated either with zoledronic acid 5 mg iv once a year or with denosumab 60 mg sc every 6 months. investigators will compare the effect of both drugs on bone turnover markers and basic laboratory parameters after 3, 12 and 24 months of treatment, and on the bone mineral density after 12 and 24 months of treatment. all participants will take cholecalciferol 800 - 1000 iu daily.


Eligibility criteria:
inclusion criteria: * postmenopausal women (\>12 months after last menstrual period) with primary hyperparathyroidism and with osteoporosis on dual energy xray absorptiometry (dxa) (according to international society for clinical densitometry (iscd) - criteria) and/or osteoporotic fracture of the vertebra or hip exclusion criteria: * the patient is not able to give informed consent * other classic complications of primary hyperparathyroidism (e.g. kidney stones, renal insufficiency) * serum albumin-corrected calcium level \> 2.85 mmol/l (except when the patient is reluctant to undergo surgical treatment) * osteoporosis treatment less than a year ago, less than two years ago in the case of oral bisphosphonate, less than three years ago in the case of parenteral bisphosphonate * bilateral hip endoprosthesis * additional causes for secondary osteoporosis (other than vitamin d deficiency) and pathological laboratory findings that are incompatible with the summary of product characteristics (smpc) of both medicines * cancer, except if in stable remission of more than 5 years

Keywords: zoledronic acid denosumab primary hyperparathyroidism osteoporosis
propofol or benzodiazepine combined with ketamine for procedural sedation in emergency setting

Conditions: Procedural Sedation

Summary: this single blinded parallel randomized clinical trial will be conducted on 50 patients presented to emergency department of alexandria main university hospital who are indicated for procedural sedation. all patients included in the study will be allocated randomly using computer software with concealment of randomization in to two groups: * group a: 25 patients will receive ketamine (0.5 mg/kg) plus midazolam (0.05 mg/kg) * group b: 25 patients will receive ketamine (0.5 mg/kg) plus propofol (0.5 mg/kg) additional ketamine (0.25 mg/kg) will be administered in case of inadequate sedation in both groups. the two groups will be compared as regard incidence of complications world society of intravenous anesthesia (siva) international sedation task force to standardize reporting adverse events


Eligibility criteria:
inclusion criteria: * adult patients (≥18 years) requiring procedural sedation and analgesia for painful procedures in ed . the following procedures are indications for psa: * cardioversion * reduction of fracture or joint dislocation * procedures as central venous catheter (cvc) and chest tube insertion or wound management exclusion criteria: * patients with anticipated difficult airway. * post cardiac arrest patients. * contraindication to study drugs. * pregnant women. * patients \> 65 years.

Keywords: midazolam propofol ketamine procedural sedation
retrospective study on the direction of artificial intelligence in identifying cranial trauma ct imaging

Conditions: Cerebral Hemorrhage

Summary: the goal of this observational retrospective study is to evaluate artificial intelligences (ai)'s proficiency in identifying and annotating brain bleeds in computed tomography (ct) images. the main questions it aims to answer are: * whether ais at present are capable of analyzing and recognizing cerebral traumas in ct images? * if they are, how competent are they and how can humans take advantages of that? ct images were selected during the normal diagnosis and treatment process of patients, and no one needed to undergo any additional procedures connected to the study.


Eligibility criteria:
inclusion criteria: * people who had cerebral traumas with brain bleedings shown in ct images. exclusion criteria: * brain bleedings were not clear or representative in ct images.

Keywords: artificial intelligence computed tomography
role of et-1, physical activity, and sedentary behavior in microvascular dysfunction following gdm

Conditions: Gestational Diabetes; Endothelial Dysfunction; Physical Inactivity

Summary: women with a history of gestational diabetes mellitus (gdm) are at a 2-fold greater risk for the development of overt cardiovascular disease (cvd) following the effected pregnancy. while subsequent development of type ii diabetes elevates this risk, prior gdm is an independent risk factor for cvd morbidity, particularly, within the first decade postpartum. gdm is associated with impaired endothelial function during pregnancy and decrements in macro- and microvascular function persist postpartum, despite the remission of insulin resistance following delivery. collectively, while the association between gdm and elevated lifetime cvd risk is clear, and available evidence demonstrates a link between gdm and vascular dysfunction in the decade following pregnancy, the mechanisms mediating this persistent dysfunction remain unexamined. the purpose of this investigation is to examine the role of endothelin-1, a potent vasoconstrictor, in aberrant microvascular function in otherwise healthy women with a history of gdm and to identify whether this mechanism is influenced by physical activity and sedentary behavior.


Eligibility criteria:
inclusion criteria * history of pregnancy within 5 years of the study visit * had healthy pregnancy or had gestational diabetes diagnosed by their obstetrician and confirmed according to the american college of obstetricians and gynecologists criteria for gestational diabetes. exclusion criteria * skin diseases, * current tobacco or electronic cigarette/vape pen use, * diagnosed or suspected hepatic or metabolic disease including diabetes, * statin or other cholesterol-lowering medication, * current antihypertensive medication, * history of preeclampsia or gestational hypertension * current hypertension, * current pregnancy, * body mass index \<18.5 kg/m2, * allergy to materials used during the experiment.(e.g. latex), known allergies to study drugs.
is kinesio taping effective to the radial nerve in patients with lateral epicondylitis?

Conditions: Lateral Epicondylitis

Summary: lateral epicondylitis (le) is the most frequent painful musculoskeletal condition, which is characterized by a pain in the lateral epicondyle of the humerus and the common extensor tendon. the incidence of le is approximately one to three percent of general population. le is mostly the result of the overuse and repetitive movements of wrists and hands because of occupational or recreational activities. diagnosis depends on clinical symptoms, history and physical examination including manual provocation tests. magnetic resonance imaging, ultrasound (us), x-ray and electrophysiological assessment may be used in patient who do not response to conservative treatments. it is known that the radial nerve cross sectional-areas (csas) are increased in cases of refractory le, although nerve conduction studies are normal. there is insufficient evidence to prove the superiority of any of conservative treatments to the others in patients with le. the literature indicates that kinesio taping decreases pain intensity, recovers grip strength, and improves functional status in patients with le. the investigators design a randomized, single-blind, controlled trail to evaluate the effects of kinesio taping both clinical and using ultrasonography.

after obtaining written informed consent, patients of clinically diagnosed with le are randomized into intervention and control group. to all patients, activity modification is suggested and 750 mg/day oral naproxen is administered for 10 days. additionally, in intervention group, kinesio tape was applied 3 times a week for 2 weeks with a total of 6 sessions. the primary outcome is visual analog scale (vas) and secondary outcomes include the patient-rated forearm evaluation questionnare (prteq), cet thickness and radial nerve csas. the evaluation was performed pretreatment as well as on the 2nd week, and 6th week after the treatment.

Eligibility criteria:
inclusion criteria: * the presence of pain in the lateral elbow region at least for three months * tenderness around the lateral humeral epicondyle following at least one of these provocation tests: resisted wrist extension, resisted middle finger extension or passive stretch of wrist extensors. exclusion criteria: * bilateral le * presence of trigger point in the extensor muscles of the forearm * history of proximal upper extremity or neck symptoms * cervical pathology * central or peripheral neurologic disease * nerve entrapment syndromes * surgical treatments for le * presence of condition that may prevent the patient using nsaids (i.e. gastrointestinal disorders, using anticoagulant) * trauma history of upper extremity * previous steroid injection around the lateral epicondyle * physical therapy targeted for le in the past 6 months * presence of structures like fibrous bands, arc or recurrent radial artery around the radial nerve that may cause the entrapment of nerve * pregnancy and having any systemic disease that may cause swelling at nerves such as diabetes mellitus, renal insufficiency, thyroid disease or rheumatic disease.
study of sgr-1505 in mature b-cell neoplasms

Conditions: Mature B-Cell Neoplasm; Non Hodgkin Lymphoma; DLBCL; Waldenstrom Macroglobulinemia; MALT Lymphoma; Follicular Lymphoma; Pediatric-Type Follicular Lymphoma; IRF4 Gene Rearrangement; EBV-Positive DLBCL, Nos; Burkitt Lymphoma; Plasmablastic Lymphoma; High-grade B-cell Lymphoma; Primary Cutaneous Follicle Center Lymphoma; Primary Effusion Lymphoma; Mantle Cell Lymphoma; DLBCL Germinal Center B-Cell Type; Primary Mediastinal Large B Cell Lymphoma; T-Cell/Histiocyte Rich Lymphoma; ALK-Positive Large B-Cell Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma; Splenic Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia; Nodal Marginal Zone Lymphoma; HHV8-Positive DLBCL, Nos; Lymphoplasmacytic Lymphoma; Duodenal-Type Follicular Lymphoma

Summary: the purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (mtd) or maximum administered dose (mad) and/or recommended dose (rd) of sgr-1505.

this is a study of sgr-1505, an oral inhibitor of malt1, in subjects with relapsed/refractory (r/r) b-cell lymphomas to evaluate the safety, pharmacokinetics (pk), pharmacodynamics (pd), maximum tolerated dose (mtd) or maximum administered dose (mad) and/or recommended dose (rd) of sgr-1505. exploratory cohorts will evaluate additional pk, pd, preliminary anti-tumor activity, and safety to establish the sgr-1505 rd. a planned amendment will evaluate sgr-1505 in combination with other anti-cancer agents, such as btk and bcl-2 inhibitors, in patients with specific b-cell malignancies.

Eligibility criteria:
inclusion criteria: * subject must have a history of histologically or cytologically confirmed mature b-cell malignancy. * subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * life expectancy ≥ 12 weeks. exclusion criteria: * the subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit). * subject has previous invasive malignancy in the last 2 years. * subject has a known allergy to sgr-1505 or excipients of sgr-1505. * subject has symptomatic or active cns involvement of disease. * any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug.

Keywords: malt1 nf-kb
adefovir dipivoxil in compensated chronic hepatitis b patients

Conditions: Chronic Hepatitis B

Summary: this study is designed to compare the efficacy and safety of adefovir dipivoxil 10 mg with lamivudine 100 mg in japanese patients with compensated chronic hepatitis b over 52-week periods.


Eligibility criteria:
inclusion criteria: * have compensated chronic hepatitis b. * have not been treated with anti hbv agents with antiproliferative activity against. however, previous interferon (ifn) therapy is permitted. * ability to read, understand, and sign the informed consent. * have a positive serum hbv-dna \>= 1,000,000 copies/ml and alt level 50-500 u/l exclusion criteria: * having or suspected of having liver cancer. * co-infected with hepatitis c virus (hcv) or human immunodeficiency virus (hiv). * autoimmune hepatitis. * received any previous transplantation or having a plan for any transplantation. * existence of any serious complication, except hepatitis b.

Keywords: treatment naive chb adefovir monotherapy
effect of milk-free diet on weight and irritable bowel syndrome in morbid obesity

Conditions: Obesity, Morbid

Summary: innlandet hospital in gjøvik is a center for patients suffering from morbid obesity in hedmark og oppland, norway. patients with either bmi \> 40 kg/m2 or with bmi \> 35 kg/m2 and complications who opt for "gastric bypass" surgery, go through a standard program including a thorough clinical examination and information on the operation, followed by a learning and coping program that consists of standard dietary advise for weight loss and includes weekly visits during 8 weeks. this research project concerns a subgroup in the patient population described above: morbidly obese patients with irritable bowel syndrome (ibs). in this group it will be investigated how an 8 week preoperative milk-free diet affects digestive functions and weight loss. it is known that milk may cause stomach complaints and may make it more difficult to loose weight.


Eligibility criteria:
inclusion criteria: * morbid obesity exclusion criteria: * no consent * contraindications to surgery

Keywords: gastric bypass questionnaires diet milk
evaluation to assess the long term safety of tacrolimus ointment for atopic dermatitis

Conditions: Atopic Dermatitis

Summary: to assess the long-term safety of tacrolimus ointment

to assess the long-term safety of tacrolimus ointment 0.03% or 0.1% in the treatment of subjects with atopic dermatitis under actual use conditions, including the risk of developing cutaneous or systemic malignancies. the fda and emea approved tacrolimus ointment, 0.03% in children and 0.1% and 0.03% in adults, for the treatment of atopic dermatitis. as part of the approval process, the fda and emea requested a post-marketing commitment regarding the safety of long-term use of tacrolimus ointment in pediatric atopic dermatitis subjects.

Eligibility criteria:
inclusion criteria: * subject has/had atopic dermatitis. * subject has applied tacrolimus ointment 0.03% or 0.1% for at least 6 weeks, continuously or intermittently. this may include subjects who have been enrolled in previous tacrolimus ointment studies and/or subjects with commercial product exposure prior to study enrollment. * subject age at the first tacrolimus ointment exposure is/was \<16 years of age. * subject/caregiver has given written informed consent and assent as required by state and/or governmental laws, including access to all relevant clinical and medication data, and the storage and analysis of these data. * subject/caregiver agrees to comply with the program requirements including an annual physical exam and biennial dermatological exam and agrees to be contacted and provide information as described in this document to primary investigator dr. lamb and covance periapproval services, inc. exclusion criteria: * subjects who do not have/ have not had atopic dermatitis. * subjects must have used tacrolimus ointment prior to age 16.
comparison of airtraq in class 2-3 obese and nonobese men during intubation: a prospective randomized clinical study

Conditions: Obesity, Morbid; Intubation; Difficult or Failed; Video Laryngoscope; Men

Summary: morbid obesity is a growing disease. intubations of these patients mostly difficult. video laryngoscopes have to be used during the intubation of these patients. the intubation of men is more complicated and difficult than obese women. there were no trials compared to the new video laryngoscopes in morbidly obese men. patients will be divided into two groups; non-obese and klas 2-3 obese. airtraq will be used for their intubation. the time for intubation will be the primary aim of this prospective randomized study. the insertion time, perioperative hemodynamic variables, and postoperative complications will also be recorded.

morbid obesity is a growing disease. intubations of these patients mostly difficult. video laryngoscopes have to be used during the intubation of these patients. the intubation of men is more complicated and difficult than obese women. there were no trials compared to the new video laryngoscopes in morbidly obese men. patients will be divided into two groups; non-obese and klas 2-3 obese. airtraq will be used for their intubation. the time for intubation will be the primary aim of this prospective randomized study. the insertion time, need of optimization menuvers, perioperative hemodynamic variables, and postoperative complications will also be recorded.

Eligibility criteria:
inclusion criteria:\> 18 age men gender elective operation requring intuabtion - exclusion criteria:\<18 age women emergency operation -